- Home
- GAMB vs HURA Comparison
GAMB vs HURA Comparison
Compare GAMB & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAMB | HURA |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | Jersey | United States |
| Employees | N/A | 22 |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 144.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GAMB | HURA |
|---|---|---|
| Price | $2.33 | $2.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $8.36 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 945.4K | 743.6K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.06 | N/A |
| Revenue Next Year | $8.79 | N/A |
| P/E Ratio | $89.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $0.41 |
| 52 Week High | $13.05 | $3.99 |
Technical Indicators
Market Signals| Indicator | GAMB | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 22.55 | 56.69 |
| Support Level | N/A | $2.26 |
| Resistance Level | $5.67 | $2.63 |
| Average True Range (ATR) | 0.30 | 0.22 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 3.21 | 85.09 |
Price Performance
Historical ComparisonAbout GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.